Earn 3 CPD Points online
Master classes
Master classes
Cancer in Africa – what are the challenges?
Prof Lynette Denny Department of Obstetrics and Gynaecology, University of Cape Town
Inequity is dramatically evident when one considers the fate of cancer patients in Africa. Epidemiological data shows that 80% of deaths from non-communicable diseases (NCD) (cardiovascular and cancer) occur in Low and Middle-Income Countries.1 In fact, the probability of dying between the ages of 30-70 years from NCD is highest in sub-Saharan Africa. In 2012, there were 14.1 million new incident cases of cancer; of which
60% occurred in Low and Middle-Income Countries. Among women, cervical cancer is the fourth most important cancer globally, while in Africa it is the second-most important cancer topped by the incidence of breast cancer (Figure 1)2. The mortality of cervical cancer in Africa is higher than breast cancer due to the lateness of presentation in Africa.
Unknown Liver Thyroid Ovary Uterus Stomach Cervix Lung Colorect Breast 0
1000000 Mortality
2000000 Incidence
Figure 1. Top ten cancers in women in Africa This Master Class was made possible by an unrestricted educational grant from Roche Diagnostics, which had no control over content
There are serious problems with the accuracy of statistics in Africa and other developing countries, because very few deaths (7% in Africa) are medically certified. There is a new drive to establish cancer registries with promising efforts in Zimbabwe, South Africa, Uganda and Gambia. Health expenditure per capita is very low in Africa and since the 1980’s, the policy of stopping free healthcare and
moving to a user-payment system has led to a major reduction in the use of health care. The highest proportion of out-ofown pocket expenditure is found in poor countries and this has resulted in a major reduction in the use of Healthcare; as an example in Nigeria, 62% of total expenditure is out-of-own-pocket expenditure, while in the USA out-of-pocket expenditure is 12%, in the UK 6%. September 2015
1
Master classes
The challenges to treating cancer in Africa are enormous: 2 existing registries in Gambia and Uganda have shown that only between 13-22% of people diagnosed with cancer survived for 5 years.3 Radiation facilities which are required for about 50% of cancer cases are inadequate in Africa, according to a recent survey (Table 1)4 [Radiation facilities in Africa]. Only 20 out of 52 countries offered brachytherapy which is an essential modality for cervical cancer therapy. South Africa and Egypt are the only African countries which have almost sufficient radiotherapy machines with their current capability reaching almost 80% of the international norm.4
Table 1. Radiation facilities in Africa • IAEA analysis of 52 countries in 2010 • 23 offered external beam radiotherapy in 2010 –– 160 radiation centres recorded on the continent • 80 cobalt- 60 units and 189 linear accelerators –– 92 machines in South Africa and 76 in Egypt, accounting for 60% of all radiation equipment in Africa • Only 20/52 countries offered brachytherapy • Calculated that this could only provide treatment for 24 300 patients per year Abdel Wahab, et al. Lancet Oncology 2013; 14(4):168-175.
Chemotherapy resources in Africa Effective chemotherapy requires trained oncologists, pharmacists, laboratory support and access to treatment for complications. In a study in Tanzania of a German-funded initative5, availability of appropriate chemotherapeutic drugs
was 50%, but over 70% of patients did not receive prescribed chemotherapeutic agents. When these patients resorted to private sources for their therapy, the costs were equivalent to an average 7 months’ income.
Access to surgery It is estimated that 2 billion people worldwide do not have adequate access to surgical care. In a study of the availability of operating theatres per 100 000 of the population in sub-Saharan Africa6,
shows 1-3 operating theatres as compared to Western Europe and Australasia’s 14 operating theatres. South East Asia shows a similar availability as sub-Saharan Africa.
Palliation and Terminal Care Access to morphine in Africa is also limited7 because there are only 11 countries that allow reconstitution of oral morphine from imported powder (Figure 2) 2
September 2015
with 5 countries having access to other types of oral morphine. 38 countries in Africa have no access to opioids. Further challenges to Africa are the
Master classes
Figure 2. Morphine availability in Africa 2012
HIV/AIDs epidemic with 70% of cases being in sub-Saharan Africa contributing to the increase in cancer incidence. Health care professionals are insufficient for subSaharan Africa needs and there are limited facilities for training in anti-cancer therapies.8 In addition, the focus on increasing the numbers of community health workers is directing resources away from the vital
need to provide leadership in healthcare by giving priority to the education and retention of medical doctors. Health research is also underfunded in Africa, particularly by pharmaceutical companies who know that they will need to build physical resources before embarking on useful clinical trials in Africa. There is a need to convert knowledge into action in Africa.
September 2015
3
Master classes
In conclusion, cancer in Africa is a significant health problem; there is inadequate per capita expenditure on health resulting in lack of access to treatment, high fatality rates for cancers. Investment in and cancer research on the continent is also totally inadequate.
References 1. World Health Statistics 2012 2. www.globocan 3. Sankaranarayan, et al. Lancet Oncol 2010; 111: 163173. 4. Abdel Wahab, et al. Lancet Oncol 2013; 14(4): 168-175. 5. Yohana E, et al. East Afr J Public Health 2011; 3(1): 52-57. 6. Funk LM, et al. Lancet 2010; 376c1055-1061 7. International Narcotics Control Board. 8. Lancet 2011; 377: 113-121. 9. BMJ 2005 32:705-706.
Visit www.denovomedica.com
Earn CPD points online
Click on ‘Accredited CPD/CEU programmes’. Log in or register and start earning CPD points today. Certificates will be emailed to you.
Disclaimer The views and opinions expressed in the article are those of the presenters and do not necessarily reflect those of the publisher or its sponsor. In all clinical instances, medical practitioners are referred to the product insert documentation as approved by relevant control authorities.
4
September 2015
Published by
70 Arlington Street, Everglen, Cape Town, 7550 Tel: (021) 976 0485 I info@denovomedica.com